Intensive versus standard multifactorial cardiovascular risk factor control in screen-detected type 2 diabetes: 5-year and longer-term modelled outcomes of the ADDITION-Leicester study

Diabetes/Metabolism Research and Reviews

Volumn 35, Issue 3, 2019, Pages

  Webb, David ^a   Dales, Jolyon ^a   Zaccardi, Francesco ^a   Hill, Sian ^a   Moore, Corran ^a   Farooqi, Azhar ^b   Griffin, Simon ^c   Davies, Melanie ^a   Khunti, Kamlesh ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b Leicester City Clinical Commissioning Group   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

cardiovascular intervention; complicationsdiabetesscreening

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATRIAL FIBRILLATION; BLINDNESS; BLOOD GLUCOSE MONITORING; BODY WEIGHT GAIN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL OUTCOME; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; ETHNIC DIFFERENCE; FEMALE; HEALTH CARE ACCESS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MICROANGIOPATHY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCREENING; SOUTH ASIAN; STANDARD; SYSTOLIC BLOOD PRESSURE; AGED; COMPARATIVE STUDY; COMPLICATION; FOLLOW UP; MASS SCREENING; PROGNOSIS; RISK FACTOR; STATISTICAL MODEL;

ADULT; AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; PROGNOSIS; RISK FACTORS;

EID: 85058845743     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.3111     Document Type: Article

References (26)

1. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-591.
2. Gaede P, Oellgaard J, Cartensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59(11):2298-2307.
3. Piepoli MF. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37(29):2315-2381.
4. American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care. 2017;40(suppl 1):S75-S87.
5. Jax TW. Metabolic memory: a vascular perspective. Cardiovasc Diabetol. 2010. 9:51. https://doi.org/10.1186/1475-2840-9-51
6. Simmons RK, Griffin SJ, Lauritzen T, Sandbaek A. Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001-2009. Diabetologia. 2017;60(11):2192-2199.
7. Herman WH, Ye W, Griffin SJ, et al. Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality: a simulation of the results of the Anglo-Danish-Dutch study of intensive treatment in people with screen-detected diabetes in primary care (ADDITION- Europe). Diabetes Care. 2015;38(8):1449-1455.
8. Webb DR, Gray LJ, Khunti K, Campbell S, Dallosso H, Davies MJ. Contrasting cardiovascular risk profiles and prescribed cardio-protective therapies in newly-diagnosed type 2 diabetes identified through screening and standard practice. Diabetes Res Clin Pract. 2011;91(3):280-285.
9. Black JA, Sharp SJ, Wareham NJ, et al. Does early intensive multifactorial therapy reduce cardiovascular risk in individuals with screen-detected diabetes? Results from the ADDITION-Europe cluster randomised trial. Diabet Med. 2014;31(6):647-656.
10. Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet. 2011;378(9786):156-167.
11. Ueki K, Saako T, Okazaki Y, et al. Kadowaki the J-DOIT3 study group. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):951-964.
12. Webb DR, Khunti K, Srinivasan B, et al. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multifactorial cardiovascular risk intervention in people with type 2 diabetes detected by screening. Trials. 2010;11(1):16 https://doi.org/10.1186/1745-6215-11-16.
13. Webb DR, Gray LJ, Khunti K, et al. Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study. Diabetologia. 2011;54(9):2237-2246.
14. Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcome model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom prospective diabetes study; UKPDS82. Diabetologia. 2013;56(9):1925-1933.
15. nomis. Labour Market Profile—Leicester Durham: Office for National Statistics; 2017 [cited 2017 1st August]. Available from: https://www.nomisweb.co.uk/reports/lmp/la/1946157130/report.aspx
16. Gillet M, Dallosso HM, Dixon S, et al. Delivering the diabetes education and self-management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost-effectiveness analysis. Br Med J. 2010;341(aug20 1):c4093.
17. Prineas RJ, Crow RS, Zhang Z-M. The Minnesota Code Manual of Electrocardiographic Findings. Springer-Verlag London; 2010 978-1-84882-778-3. https://doi.org/10.1007/978-1-84882-778-3.
18. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17(11):1281-1289.
19. KDOQI clinical practice guidelines for diabetes and chronic kidney disease. Am J Kidney Dis. 2012;60(5):850-886.
20. Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(6):431-437.
21. Colhourn HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696.
22. Buckley LF, Dixon DL, Wohlford GF, Wijesinghe DS, Baker WL, Van Tassell BW. Intensive versus standard blood pressure control in SPRINT-eligible participants of the ACCORD-BP trial. Diabetes Care. 2017;40(12):1733-1738.
23. Paul SK, Adjah ESO, Samanta M, et al. Comparison of body mass index at diagnosis of diabetes in a multi-ethnic population: a case-control study with matched non-diabetic controls. Diabetes Obes Metab. 2017;19(7):1014-1023.
24. Jermendy G. Vascular memory: can we broaden the concept of the metabolic memory? Cardiovasc Diabetol. 2012;11(1):44.
25. Webb DR, Khunti K, Gray LJ, et al. Intensive multifactorial intervention improves modelled coronary heart disease risk in screen-detected type 2 diabetes mellitus: a cluster randomized controlled trial. Diabet Med. 2012;29(4):531-540.
26. Bannister CA, Polle CD, Jenkins-Jones S, et al. External validation of the UKPDS risk engine in incident type 2 diabetes: a need for new type 2 diabetes specific risk equations. Diabetes Care. 2014;37(2):537-545.